Janux Therapeutics Q3 net loss narrows to $11.6M; cash $349.7M supports operations through 2027

Janux Therapeutics, Inc.

2023-Q3 EPS reported -$1.08 revenue$5,622,000

Net loss $11.6M vs $16.7M YoY; R&D expenses $11.9M, G&A $6.4M.
Cash and short-term investments $349.7M, up from $327.0M at year-end 2022, expected to fund operations through 2027.
Enrollment ongoing for JANX007 (PSMA-TRACTr) in prostate cancer and JANX008 (EGFR-TRACTr) in solid tumors; update expected in 2024.
IND-enabling studies completed for JANX009 (PD-L1xCD28 TRACIr); TROP2-TRACTr candidate identified.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Janux Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $11.6 million.

Period: third quarter ended September 30, 2023
Net income: net loss of $11.6 million
Result: reported results

Exact text from the filing

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

View on SEC.gov

Browse all earnings releases →

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.